Full Papers
Alpha-Klotho protein in systemic lupus erythematosus
C. Martín-González1, F. Gómez-Bernal2, J.C. Quevedo-Abeledo3, C. Ferrer-Moure4, E. Espelosín-Ortega5, M.Á. González-Gay6, I. Ferraz-Amaro7
- Division of Internal Medicine, Hospital Universitario de Canarias, Tenerife, and Department of Internal Medicine, University of La Laguna, Tenerife, Spain.
- Division of Central Laboratory, Hospital Universitario de Canarias, Tenerife, Spain.
- Division of Rheumatology, Hospital Doctor Negrín, Las Palmas de Gran Canaria, Tenerife, Spain.
- Division of Central Laboratory, Hospital Universitario de Canarias, Tenerife, Spain.
- Division of Central Laboratory, Hospital Universitario de Canarias, Tenerife, Spain.
- Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander; Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, Universidad de Cantabria, Santander, Spain; and Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. miguelaggay@hotmail.com
- Department of Internal Medicine, University of La Laguna, Tenerife, and Division of Rheumatology, Hospital Universitario de Canarias, Tenerife, Spain. iferrazamaro@hotmail.com
CER15444
2023 Vol.41, N°1
PI 0041, PF 0047
Full Papers
Free to view
(click on article PDF icon to read the article)
PMID: 35349421 [PubMed]
Received: 26/12/2021
Accepted : 21/02/2022
In Press: 11/03/2022
Published: 23/01/2023
Abstract
OBJECTIVES:
Alpha-Klotho protein (α-Klotho) is an essential component of endocrine fibroblast growth factor receptor complexes that governs multiple metabolic processes including aging-related disorders, diabetes, cancer, arteriosclerosis, and chronic kidney disease. Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that can affect almost any organ in the body and in which multiple pathophysiological abnormalities are observed. In the present work, our objective was to study whether the serum levels of α-Klotho differ between patients with SLE and controls, and how this protein is related to the clinical and laboratory characteristics of the disease.
METHODS:
Cross-sectional study that included 364 women, 195 of them diagnosed with SLE and 169 sex- and age-matched controls. Circulating α-Klotho was analysed in SLE patients and controls. A multivariable analysis was performed to assess whether α-Klotho differs between patients and controls, and to study its relationship with SLE features.
RESULTS:
No differences were found in α-Klotho levels between SLE patients and controls, both in univariable and multivariable analyses. Disease-related data like SLE duration, acute phase reactants, activity, severity and damage indices, and autoantibodies profile were not significantly associated with serum levels of α-Klotho. However, the use of prednisone and the presence of musculoskeletal manifestations were significantly related to higher α-Klotho serum levels.
CONCLUSIONS:
α-Klotho protein serum levels do not differ between patients with SLE and controls. Nevertheless, SLE patients taking prednisone or those with musculoskeletal manifestations show significantly higher circulating levels of α-Klotho.
